5-甲氧基水杨酸胺 | 28534-37-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-甲氧基水杨酸胺
• 中文别名: 2-氨基-4,5-二甲基-1-苯基-1H-吡咯-3-腈
• 英文名称: 2-hydroxy-5-methoxybenzamide
• 英文别名: 5-methoxysalicylamide
• CAS: 28534-37-4
• 化学式: C₈H₉NO₃
• mdl: MFCD00191177
• 分子量: 167.164
• InChiKey: VLSVEVCSHFHKEM-UHFFFAOYSA-N

物化性质

• 沸点：
  320.5±32.0 °C(Predicted)
• 密度：
  1.280±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  5-甲氧基水杨酸胺 在 吡啶 作用下， 反应 3.0h， 生成 2-(2-Fluoro-phenyl)-6-methoxy-benzo[e][1,3]oxazin-4-one
  参考文献：
  名称：

  Synthesis of Some 2-Aryl-1,2,4-triazolo[1,5-c][1,3]benzoxazin-5-ones as Tools To Define the Essential Pharmacophoric Descriptors of a Benzodiazepine Receptor Ligand

  摘要：

  The synthesis and benzodiazepine receptor (BZR) affinity of some 1,2,4-triazolo[1,5-c][1,3]benzoxazin-5-ones, 2-22, are reported. Compounds 2-22 are devoid of the proton donor group, which according to a BZR schematic model was one of the pharmacophoric descriptors for receptor-ligand interaction. The binding data show that 2-(2-fluorophenyl)-9-chloro-1,2,4-triazolo[1,5-c][1,3]benzoxazin-5-one (12) and some other compounds display nanomolar BZR affinity, indicating that the hydrogen donor group is not essential for the anchoring of 6,6,5-tricyclic systems to the BZR but only affects the potency of a ligand.

  DOI：

  10.1021/jm00012a020
• 作为产物：
  描述：

  5-甲氧基水杨酸 在 氨 、 caesium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.67h， 生成 5-甲氧基水杨酸胺
  参考文献：
  名称：

  ¹¹C- and¹⁸F-Labeled Radioligands for P-Glycoprotein Imaging by Positron Emission Tomography

  摘要：

  AbstractP‐Glycoprotein (P‐gp) is an efflux transporter widely expressed at the human blood–brain barrier. It is involved in xenobiotics efflux and in onset and progression of neurodegenerative disorders. For these reasons, there is great interest in the assessment of P‐gp expression and function by noninvasive techniques such as positron emission tomography (PET). Three radiolabeled aryloxazole derivatives: 2‐[2‐(2‐methyl‐(11C)‐5‐methoxyphenyl)oxazol‐4‐ylmethyl]‐6,7‐dimethoxy‐1,2,3,4‐tetrahydroisoquinoline ([11C]‐5); 2‐[2‐(2‐fluoromethyl‐(18F)‐5‐methoxyphenyl)oxazol‐4‐ylmethyl]‐6,7‐dimethoxy‐1,2,3,4‐tetra‐hydroisoquinoline ([18F]‐6); and 2‐[2‐(2‐fluoroethyl‐(18F)‐5‐methoxyphenyl)oxazol‐4‐ylmethyl]‐6,7‐dimethoxy‐1,2,3,4‐tetrahydroisoquinoline ([18F]‐7), were tested in several in vitro biological assays to assess the effect of the aryl substituent in terms of potency and mechanism of action toward P‐gp. Methyl derivative [11C]‐5 is a potent P‐gp substrate, whereas the corresponding fluoroethyl derivative [18F]‐7 is a P‐gp inhibitor. Fluoromethyl compound [18F]‐6 is classified as a non‐transported P‐gp substrate, because its efflux increases after cyclosporine A modulation. These studies revealed a promising substrate and inhibitor, [11C]‐5 and [18F]‐7, respectively, for in vivo imaging of P‐gp by using PET.

  DOI：

  10.1002/cmdc.201500420

文献信息

• Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur
  申请人：A. H. Robins Company, Inc.

  公开号：US04705853A1

  公开（公告）日：1987-11-10

  Aromatic azepinones and thiones having the formula ##STR1## wherein; A is benzene, naphthalene, quinoline or pyridine; B is oxygen or sulfur; E is oxygen, sulfur or ##STR2## n is 1, 2 or 3; Z is an amino or a heterocyclic nitrogen-containing radical; R is hydrogen, loweralkyl, cycloalkyl or phenylloweralkyl; Y is halo, loweralkyl, loweralkoxy, diloweralkylamino, nitro, amino, loweracetylamino, trifluoromethyl, phenyl or phenyl substituted by one to three Y' radicals selected from halo, loweralkyl, loweralkoxy, diloweralkylamino, nitro, amino, loweracylamino or trifluoromethyl; and having antihistaminic utility, a process for the preparation thereof and chemical intermediates therefor are disclosed.

  芳香族氮杂七元酮和硫醚的化学式为##STR1##其中；A为苯、萘、喹啉或吡啶；B为氧或硫；E为氧、硫或##STR2##n为1、2或3；Z为氨基或含氮杂环的基团；R为氢、较低烷基、环烷基或苯基较低烷基；Y为卤素、较低烷基、较低烷氧基、二较低烷基氨基、硝基、氨基、较低乙酰氨基、三氟甲基、苯基或被从卤素、较低烷基、较低烷氧基、二较低烷基氨基、硝基、氨基、较低酰胺基或三氟甲基中选择的一个至三个Y'基团取代的苯基；具有抗组胺作用，公开了其制备方法和化学中间体。
• 1,6-Dihydro-6-oxo-2-(ortho-substituted phenyl)pyrimidine-5-carboxylic
  申请人：Bristol-Myers Company

  公开号：US04031093A1

  公开（公告）日：1977-06-21

  A series of 1,6-dihydro-6-oxo-2-(ortho-substituted phenyl)pyrimidine-5-carboxylic acid derivatives is provided for use as inhibitors of allergic reactions. The compounds show antiallergy activity by both oral and parenteral routes of administration.

  提供了一系列1,6-二氢-6-氧-2-(邻位取代苯基)嘧啶-5-羧酸衍生物，用作抗过敏反应的抑制剂。这些化合物通过口服和注射途径展现抗过敏活性。
• Asymmetric Hydrogenation of Cationic Intermediates for the Synthesis of Chiral <i>N</i> , <i>O</i> ‐Acetals
  作者：Yongjie Sun、Qingyang Zhao、Heng Wang、Tilong Yang、Jialin Wen、Xumu Zhang

  DOI：10.1002/chem.202002930

  日期：2020.9.4

  study, we were seeking a breakthrough in asymmetric hydrogenation, with cationic intermediates as targets, and thereby anticipating applying this powerful tool to the construction of challenging chiral molecules. Under acidic conditions, both N‐ or O‐acetylsalicylamides underwent cyclization to generate cationic intermediates, which were subsequently reduced by an iridium or rhodium hydride complex. The

  半个多世纪以来，过渡金属催化的均相加氢主要集中在中性和易于制备的不饱和底物上。尽管将分子氢加到C = C，C = N和C = O键上代表了一个经过充分研究的范例，但阳离子物种的不对称氢化仍然是一个欠发达的领域。在这项研究中，我们寻求以阳离子中间体为目标的不对称氢化方面的突破，并因此有望将此强大工具应用于具有挑战性的手性分子的构建。在酸性条件下，N-或O-乙酰水杨酰胺都进行环化生成阳离子中间体，随后被铱或氢化铑配合物还原。结果N，O-乙缩醛的合成具有很高的对映选择性。这种催化策略显示出高效率（周转数高达4400）和高化学选择性。机理研究支持了阳离子中间体在原位形成并随后氢化的假说。已经提出了催化循环，其中氢化物从铱配合物转移到阳离子sp 2碳原子是决定速率的步骤。已经创建了催化剂的空间图以说明手性环境，并且定量结构-选择性关系分析显示了在此化学转化中如何实现对映异构体诱导。
• N-Phosphinyl Phosphoramide-A Chiral Brønsted Acid Motif for the Direct Asymmetric N,O-Acetalization of Aldehydes
  作者：Sreekumar Vellalath、Ilija Čorić、Benjamin List

  DOI：10.1002/anie.201005347

  日期：2010.12.10

  Fine‐tuning the sites: The readily accessible N‐phosphinyl phosphoramide 1 proved to be highly efficient and enantioselective in catalyzing the title reaction. The synthetic utility of this methodology was demonstrated with the first catalytic asymmetric synthesis of the analgesic pharmaceutical (R)‐chlorothenoxazine (see scheme).

  位点的微调：容易获得的N-次膦酰基磷酰胺1在催化标题反应中被证明是高效且对映选择性的。止痛药（R）-氯代噻嗪的首次催化不对称合成证明了该方法的合成效用（参见方案）。
• Modulators of Acetyl-Coenzyme A Carboxylase and Methods of Use Thereof
  申请人：Anderson Richard

  公开号：US20100009982A1

  公开（公告）日：2010-01-14

  The present invention provides compounds of formula I: along with methods of use of these compounds as pharmaceuticals, particularly in the treatment of obesity, metabolic syndrome, atherosclerosis, cardiovascular disease, insulin resistance, diseases associated with reduced neuronal metabolism, and cancer as well as the use of these compounds for treatment of pathogens of humans and animals, and for the control of agricultural pests, particularly fungi, weeds and insects.

  本发明提供了I式化合物，以及这些化合物作为药物的使用方法，特别是在肥胖、代谢综合征、动脉粥样硬化、心血管疾病、胰岛素抵抗、与减少神经代谢有关的疾病和癌症的治疗中的应用，以及这些化合物用于治疗人类和动物的病原体，并用于控制农业害虫，特别是真菌、杂草和昆虫。